These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 11707667)

  • 1. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
    Gerna G; Piccinini G; Genini E; Percivalle E; Zavattoni M; Lilleri D; Testa L; Comolli G; Maserati R; Baldanti F; Maccario R; Monforte AD; Revello MG
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):320-31. PubMed ID: 11707667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART.
    Tamarit A; Alberola J; Mir A; Benet I; Mira JV; Muñoz C; Galindo MJ; Navarro D
    J Clin Virol; 2004 Apr; 29(4):308-14. PubMed ID: 15018860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients.
    Lilleri D; Piccinini G; Genini E; Comolli G; Chiesa A; Tordato F; Sotgiu G; Parisi A; Baldanti F; Revello MG; Gerna G
    J Clin Virol; 2004 Apr; 29(4):297-307. PubMed ID: 15018859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response.
    Lilleri D; Piccinini G; Baldanti F; Seminari E; Galloni D; Gerna G
    J Clin Virol; 2003 Jan; 26(1):95-100. PubMed ID: 12589839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of human cytomegalovirus specific T cell immunity in human immunodeficiency virus infected patients in different disease stages following HAART and in long-term non-progressors.
    Tamarit A; Alberola J; Mira JV; Tornero C; Galindo MJ; Navarro D
    J Med Virol; 2004 Nov; 74(3):382-9. PubMed ID: 15368523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy.
    Focà E; Motta D; Pollara C; Brianese N; Gotti D; Albini L; Quiros-Roldan E; Torti C; Manca N
    New Microbiol; 2012 Apr; 35(2):227-31. PubMed ID: 22707137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis: long-Term results in a small case series.
    Reed JB; Briggs JW; McDonald JC; Freeman WR; Morse LS
    Retina; 2001; 21(4):339-43. PubMed ID: 11508879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of human cytomegalovirus-specific CD4(+) T-cell frequency and lymphoproliferative response in human immunodeficiency virus-positive patients.
    Piccinini G; Comolli G; Genini E; Lilleri D; Gulminetti R; Maccario R; Revello MG; Gerna G
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1225-30. PubMed ID: 11687467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy.
    Deayton JR; Sabin CA; Britt WB; Jones IM; Wilson P; Johnson MA; Griffiths PD; Emery VC
    AIDS; 2002 Nov; 16(16):2129-35. PubMed ID: 12409733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy.
    Torriani FJ; Freeman WR; Macdonald JC; Karavellas MP; Durand DM; Jeffrey DD; Meylan PR; Schrier RD
    AIDS; 2000 Jan; 14(2):173-80. PubMed ID: 10708288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease.
    Verbraak FD; Boom R; Wertheim-van Dillen PM; van den Horn GJ; Kijlstra A; de Smet MD
    Br J Ophthalmol; 1999 Oct; 83(10):1186-9. PubMed ID: 10502584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease.
    Alberola J; Tamarit A; Cardeñoso L; Estellés F; Igual R; Navarro D
    J Med Virol; 2001 May; 64(1):35-41. PubMed ID: 11285566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
    Komanduri KV; Feinberg J; Hutchins RK; Frame RD; Schmidt DK; Viswanathan MN; Lalezari JP; McCune JM
    J Infect Dis; 2001 Apr; 183(8):1285-9. PubMed ID: 11262214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy.
    Song MK; Karavellas MP; MacDonald JC; Plummer DJ; Freeman WR
    Retina; 2000; 20(2):151-5. PubMed ID: 10783947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.
    Jouan M; Savès M; Tubiana R; Carcelain G; Cassoux N; Aubron-Olivier C; Fillet AM; Nciri M; Sénéchal B; Chêne G; Tural C; Lasry S; Autran B; Katlama C;
    AIDS; 2001 Jan; 15(1):23-31. PubMed ID: 11192865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.